• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Articles published by Eisai

    < Previous 1 2 Next >
    Lecanemab Receives Priority Review Status in Japan
    From Eisai
    Via JCN Newswire
    Tickers ESALY
    Eisai Submits Supplemental Biologics License Application to FDA for Traditional Approval of LEQEMBI (lecanemab-irmb) for the Treatment of Alzheimer's Disease
    From Eisai
    Via JCN Newswire
    Tickers ESALY
    FDA Approves LEQEMBI (lecanemab-irmb) Under the Accelerated Approval Pathway for the Treatment of Alzheimer's Disease
    From Eisai
    Via JCN Newswire
    Tickers ESALY
    Astellas, Eisai, Daiichi Sankyo and Takeda Agree to Collaborate to Reduce Environmental Burden in the Field of Pharmaceutical Packaging
    From Eisai
    Via JCN Newswire
    Tickers ESALY
    Eisai to Divest Rights for Anti-Epileptic Drug Fycompa (perampanel) CIII in United States to Catalyst Pharmaceuticals
    From Eisai
    Via JCN Newswire
    Tickers ESALY
    Eisai and Washington University School of Medicine in St. Louis Enter Into Comprehensive Research Collaboration Agreement Aiming to Create New Therapies for Neurodegenerative Diseases
    From Eisai
    Via JCN Newswire
    Tickers ESALY
    Eisai to Present Preclinical and Clinical Research on Eribulin at the 2022 San Antonio Breast Cancer Symposium
    From Eisai
    Via JCN Newswire
    Tickers ESALY
    Eisai Announces Approval of Partial Change to Label for Dosage and Administration of Aricept for Treatment of Dementia with Lewy Bodies
    From Eisai
    Via JCN Newswire
    Tickers ESALY
    Eisai to Present Latest Data on Perampanel at the 76th American Epilepsy Society (AES) Annual Meeting
    From Eisai
    Via JCN Newswire
    Tickers ESALY
    Eisai Announces Acquisition of Arteryex Shares (Making Arteryex a Subsidiary) to Strengthen and Rapidly Expand the Foundation of its Digital Solution Business
    From Eisai
    Via ACN Newswire
    Eisai Presents Full Results of Lecanemab Phase 3 Confirmatory Clarity Ad Study for Early Alzheimer's Disease at Clinical Trials on Alzheimer's Disease (CTAD) Conference
    From Eisai
    Via JCN Newswire
    Tickers ESALY
    To Develop Japan's First Blood Biomarker-Based Diagnostic Workflow for Dementia Shimadzu, Eisai, Oita University, and Usuki City Medical Association Commence Joint Research
    From Eisai
    Via JCN Newswire
    Tickers ESALY
    Eisai: Announcement About an Approval for Additional Indication of Jyseleca, JAK inhibitor
    From Eisai
    Via ACN Newswire
    Eisai: Latest Findings on Lecanemab Presented at AD/PD 2022 Annual Meeting
    From Eisai
    Via ACN Newswire
    Eisai: Economic Arrangements of Amendment to Alzheimer's Disease Treatment Collaboration Agreement with Biogen
    From Eisai
    Via ACN Newswire
    Biogen and Eisai Amend Collaboration Agreements on Alzheimer's Disease Treatments
    From Eisai
    Via ACN Newswire
    Eisai: LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Approved in Japan for Radically Unresectable or Metastatic Renal Cell Carcinoma
    From Eisai
    Via ACN Newswire
    Eisai Receives the Tokyo Governor Prize for Corporate Governance of the Year 2021
    From Eisai
    Via ACN Newswire
    Eisai: Lenvima (Lenvatinib) in Combination with Keytruda (Pembrolizumab) Approved in Taiwan for the First-Line Treatment of Patients with Advanced Renal Cell Carcinoma
    From Eisai
    Via ACN Newswire
    Eisai Announces Results and Continued Support of Initiatives for Elimination of Neglected Tropical Diseases
    From Eisai
    Via ACN Newswire
    Eisai: Update on the Phase 4 ENVISION Confirmatory Study of ADUHELM
    From Eisai
    Via ACN Newswire
    Eisai: Results From Pivotal Phase 3 Study 309/KEYNOTE-775 Trial of LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) in Advanced Endometrial Carcinoma
    From Eisai
    Via ACN Newswire
    Eisai Listed as a Global 100 Most Sustainable Corporation for the Sixth Time
    From Eisai
    Via ACN Newswire
    Eisai's Anti-amyloid Beta Protofibril Antibody Lecanemab Selected as the Background Therapy for the Tau Nexgen Study
    From Eisai
    Via ACN Newswire
    Eisai to Present Abstracts on Lenvatinib at 2022 ASCO Gastrointestinal Cancers Symposium
    From Eisai
    Via ACN Newswire
    Eisai to Launch Digital Too "Cogmate" in Taiwan and Hong Kong for Self-Assessment of Brain Performance (Brain Health)
    From Eisai
    Via ACN Newswire
    Eisai Enters Into Exclusive Licensing Agreement with Roivant Concerning Investigational Anticancer Agent H3B-8800, a Splicing Modulator
    From Eisai
    Via ACN Newswire
    Investigational Alzheimer's Disease Therapy Lecanemab Granted FDA Fast Track Designation
    From Eisai
    Via ACN Newswire
    Biogen Announces Reduced Price for Aduhelm to Improve Access For Patients With Early Alzheimer's Disease In The United States
    From Eisai
    Via ACN Newswire
    Eisai Enters into Commercialization and Distribution Agreement with Gilead for JAK Inhibitor Filgotinib in Asia
    From Eisai
    Via ACN Newswire
    < Previous 1 2 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.